肝細(xì)胞癌（hepatocellular carcinoma,HCC）是肝臟最常見的惡性腫瘤,在世界范圍內(nèi)普遍流行,最新的流行病學(xué)調(diào)查顯示,其發(fā)病率位于所有惡性腫瘤中第五位,腫瘤致死性疾病中第三位,并且發(fā)病率具有一定的性別差異,于男性中排名第三位,女性中第八位。HCC生長速度快、惡性程度高,常伴有血管侵犯、肝內(nèi)及肝外轉(zhuǎn)移、治療后復(fù)發(fā)等,預(yù)后差,其5年生存率僅僅為3%-25%,嚴(yán)重危害著人類的健康。目前仍未完全闡明HCC的發(fā)病機(jī)制,因此,探究新的分子靶點(diǎn)及信號通路具有重要的科研及臨床意義。Micro RNAs（miRNAs）是一類單鏈的,長度約為14-24個核苷酸,非編碼的小RNA片段,可以特異性結(jié)合至靶基因的3’末端非翻譯區(qū)（3’end of the untranslated regions,3’-UTR）,導(dǎo)致靶基因的降解或抑制靶基因的翻譯,從而調(diào)控多個生理及病理過程,例如細(xì)胞增殖、周期、分化、凋亡等基本生命過程。大量的研究結(jié)果顯示,miRNA在腫瘤的發(fā)生發(fā)展過程中扮演了促癌或抑癌的角色,miRNA的功能失調(diào)會影響腫瘤的發(fā)生及進(jìn)展。miRNA可能成為腫瘤診斷、治療的一個潛在的小分子生物... 

【文章來源】：河北醫(yī)科大學(xué)河北省

【文章頁數(shù)】：125 頁

【學(xué)位級別】：博士

【部分圖文】：

糖酵解在miR-342-3p抑制HepG2細(xì)胞增殖中發(fā)揮了重要作用Fig.1miR-342-3psuppressedthecellproliferationandcolonyformationabilityinHepG2hepatomacells.2-deoxy-D-glucose(2-DG),theglycolyticinhibitor,impairedtheabilityofmiR-342-3pmimicstoinhibitproliferation

26圖 2 糖酵解在miR-342-3p抑制MHCC97H細(xì)胞增殖中發(fā)揮了重要作用Fig. 2 miR-342-3p suppressed the cell proliferation and colony formationability in MHCC97H hepatoma cells. 2-deoxy-D-glucose (2-DG), theglycolytic inhibitor, impaired the ability of miR-342-3p mimics to inhibitproliferation and colony formation in MHCC97H hepatoma cells.**P < 0.01

1 IGF-1R 是 miR-342-3p 的靶 target of miR-342-3p in HEKells transfected with NC or mve control. β–actin was used a

【參考文獻(xiàn)】：
期刊論文
[1]Metabolic positron emission tomography imaging of cancer:Pairing lipid metabolism with glycolysis[J]. Sandi A Kwee,John Lim.  World Journal of Radiology. 2016(11)
[2]Hepatocellular carcinoma and hepatitis B surface protein[J]. Yong-Wei Li,Feng-Cai Yang,Hui-Qiong Lu,Jiong-Shan Zhang.  World Journal of Gastroenterology. 2016(06)
[3]Liver transplantation in acute liver failure:A challenging scenario[J]. Manuel Mendizabal,Marcelo Oscar Silva.  World Journal of Gastroenterology. 2016(04)
[4]Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells[J]. Yan-Ling Chen,Jun-Jiao Song,Xiao-Chun Chen,Wei Xu,Qiang Zhi,Yun-Peng Liu,Hong-Zhi Xu,Jin-Shui Pan,Jian-Lin Ren,Bayasi Guleng.  World Journal of Gastroenterology. 2015(30)
[5]MicroRNAs: regulators of cancer metastasis and epithelialmesenchymal transition（EMT）[J]. Xiang-Ming Ding.  Chinese Journal of Cancer. 2014(03)
[6]Overexpression of insulin-like growth factor-Ⅰ receptor as a pertinent biomarker for hepatocytes malignant transformation[J]. Xiao-Di Yan,Min Yao,Li Wang,Hai-Jian Zhang,Mei-Juan Yan,Xing Gu,Yun Shi,Jie Chen,Zhi-Zhen Dong,Deng-Fu Yao.  World Journal of Gastroenterology. 2013(36)
[7]A candidate targeting molecule of insulin-like growth factor-Ⅰ receptor for gastrointestinal cancers[J]. Yasushi Adachi,Hiroyuki Yamamoto,Hirokazu Ohashi,Takao Endo,David P Carbone,Kohzoh Imai,Yasuhisa Shinomura.  World Journal of Gastroenterology. 2010(46)
[8]Reactivation of the insulin-like growth factor-Ⅱsignaling pathway in human hepatocellular carcinoma[J]. Kai Breuhahn,Peter Schirmacher.  World Journal of Gastroenterology. 2008(11)



本文編號：3235310